Renovorx Inc Stock Price, News & Analysis

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company specializing in targeted cancer therapies, announced its leadership’s involvement in two investor conferences this month. The ROTH Capital Partners 34th Annual Conference will take place from March 13-15, 2022 in Dana Point, CA, with CEO Shaun Bagai presenting on March 14 at 1:30 p.m. PT. The Maxim Virtual Growth Conference occurs from March 28-30, 2022, where Bagai will present on-demand and participate in a pancreatic cancer panel on March 28. One-on-one meetings can be scheduled with the investment community.

RenovoRx, a biopharmaceutical company, has enrolled its first patient at Columbia University for the TIGeR-PaC Phase 3 clinical trial. This trial evaluates the efficacy of the RenovoTAMP™ therapy platform as a treatment for locally advanced pancreatic cancer (LAPC). By delivering chemotherapy directly to tumors, the trial aims to improve patient outcomes compared to traditional systemic chemotherapy. The trial is currently enrolling patients across various sites in the U.S.

RenovoRx, Inc. (Nasdaq: RNXT) will host a fireside chat titled “Delivering Therapy Where it Matters” on February 23 at 12 p.m. ET, featuring CEO Shaun Bagai. The session will focus on the company's localized chemotherapy approach and its 2022 milestones. Participants can engage in a Q&A. RenovoRx is known for its RenovoTAMP therapy platform, targeting difficult tumors. Its lead candidate, RenovoGem, is being tested in the Phase 3 TIGeR-PaC trial for locally advanced pancreatic cancer.

RenovoRx, Inc. (Nasdaq: RNXT) presented its RenovoTAMP™ therapy platform at the 2022 SPECTRUM Conference in Miami. Dr. Ripal Gandhi, a Principal Investigator for the Phase 3 TIGeR-PaC clinical trial, highlighted data suggesting that RenovoTAMP, combined with radiation therapy, can significantly reduce systemic chemotherapy exposure and its associated side effects. The therapy aims to improve survival rates and quality of life for locally advanced pancreatic cancer patients. The company continues to enroll patients for the TIGeR-PaC study and anticipates releasing interim data soon.

RenovoRx, a biopharmaceutical company focused on targeted cancer therapies, will have CEO Shaun Bagai participate in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. An on-demand investor presentation will be available starting January 10 at 7:00 am EST. Management will also hold 1-on-1 meetings during the conference. RenovoRx is known for its RenovoTAMP therapy platform, which uses localized treatment for difficult tumors, and is currently studying its lead product, RenovoGem, in a Phase 3 trial for pancreatic cancer.

RenovoRx (RNXT) announced its Q3 2021 financial results, highlighting a net loss of $1.5 million, up from $1.1 million year-over-year. Research and development expenses increased to $0.8 million due to higher personnel costs. The company received its seventh U.S. patent for its RenovoTAMP™ technology and presented positive data from clinical trials, indicating a two-thirds reduction in systemic levels of gemcitabine with their intra-arterial delivery system. As of September 30, 2021, RenovoRx reported cash equivalents of $17.7 million and no debt.

RenovoRx (RNXT) announced the presentation of an ePoster at the 2021 Pancreas Club Annual Meeting, discussing the RR2 Observational Registry Study. This study validated the effectiveness of RenovoTAMP™ for intra-arterial delivery of gemcitabine in treating unresectable locally advanced pancreatic cancer (LAPC). Results highlight improved survival rates, with a median overall survival of 31.7 months for patients treated via the superior mesenteric artery. The findings support continued research in the ongoing Phase 3 TIGeR-PaC trial.

RenovoRx, Inc. (Nasdaq: RNXT) has presented preliminary pharmacokinetic data from its Phase 3 TIGeR-PaC clinical trial at the Miami Cancer Institute. Dr. Ripal Gandhi highlighted how RenovoTAMP reduces systemic gemcitabine levels by approximately two-thirds compared to IV infusion, aiming to enhance targeted treatment for locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoGem delivered through intra-arterial methods, with a focus on improving patients' quality of life while minimizing side effects associated with conventional chemotherapy.

RenovoRx, a biopharmaceutical company, announced FDA 510(k) clearance for its RenovoCath Delivery System, integral to its RenovoGem product. This dual-balloon catheter enhances targeted chemotherapy delivery to tumors, potentially improving treatment efficacy with reduced side effects. The RenovoTAMP platform, currently in the Phase 3 TIGeR-PaC clinical trial for pancreatic cancer, has seen 44% patient enrollment. In previous studies, over half of treated patients survived beyond two years, significantly better than the typical 12-15 months for standard care.